“Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news (CROSBI ID 290055)
Prilog u časopisu | ostalo
Podaci o odgovornosti
Giovanella, Luca ; Verburg, Frederik A. ; Petranović Ovčariček, Petra ; Iakovou, Ioannis ; Mihailovic, Jasna ; Vrachimis, Alexis ; Zerdoud, Slimane ; Hoffmann, Martha ; Luster, Markus
engleski
“Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide” on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news
Radioactive iodine (RAI) is widely used to treat patients with Graves’ disease, as either initial therapy or following failure of thionamides, and thyroid nodular autonomy. The recent publication of a study from Kitahara and colleagues, indicating a slightly higher relative risk of breast cancer in hyperthyroid patients receiving RAI therapy, started a large debate that is mainly focused on methodological limitations. Quite surprisingly, two of Kitahara’s study co-authors showed, using data from the same cohort, that the standardized mortality ratio (SMR) for breast cancer is higher for patients treated with antithyroid drugs compared with patients treated with RAI.
radioiodine, hyperthyroidism, mortality, antithyroid drugs
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
47 (6)
2020.
1342-1344
objavljeno
1619-7070
1619-7089
10.1007/s00259-020-04748-4
Povezanost rada
Kliničke medicinske znanosti